MALAT1 and neoplasm: (28) found that Malat1 inhibition resulted in delayed primary tumor growth in macrophage-rich T12 tumor subtypes and neutrophil-rich 2208 L tumors and a significant reduction in tumor volume in both models after 14 days of treatment.